Psoriasis : State of the art 2013 Part II :Therapeutics

[en] The treatment of psoriasis is mainly based on anti-inflammatory and/or anti-hyperproliferative agents. The topical steroids appeared in the fifties and were the first therapeutic breakthrough for psoriasis, followed by methotrexate and phototherapy in the sixties, photochemotherapy (PUVA) in the seventies and acitretin and cyclosporine in the eighties. The targeted biologic therapies represent a whole new era of therapeutic possibilities with a highly beneficial safety record. The choice of treatment depends on a large series of factors, including the type and extend of the psoriasis, the patient's preferences, co-medications, comorbidities and drug tolerance. This overview presents the currently available topical and systemic agents for treating psoriasis, including topical corticosteroids, vitamin D derivatives, UV-light based therapies, methotrexate, cyclosporine, acitretin, and the biologic agents such as the TNF antagonists etanercept, adalimumab and infliximab, as well as the anti-p40 IL12/23 agent ustekinumab. Newer, very promising, agents aiming the Th17 pathway are under development for psoriasis.

Disciplines :

Dermatology

Author, co-author :

de LA BRASSINNE, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Language :

English

Title :

Psoriasis : State of the art 2013 Part II :Therapeutics

Publication date :

2013

Journal title :

Acta Clinica Belgica

ISSN :

0001-5512

Publisher :

Acta Clinica Belgica, Bruxelles, Belgium

Volume :

68-6

Pages :

433-441

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 10 February 2015

Statistics

Number of views

80 (11 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

de la Brassinne M, Failla V, Nikkels AF. Psoriasis: State of the art 2012. Part I: clinical, historical, epidemiological and genetic aspects, co-morbidities and pathogenesis. Acta Clinica Belgica 2013, submitted for publication.
Menter A., Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1 Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95-102.
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 12-20.
Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
Augustin M, Alvaro-Garcia JM, Bagot M, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26 (suppl.4): 1-16.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 5: 383-389.
Poikolainen K, Karvonen J, Pukkula E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490-1493.
Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145: 610-616.
van de Kerkhof PC, Kragballe K, Austad J, et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006; 16: 167-171.
Berth-Jones J, Thompson J, Papp K, on behalf of the Copenhagen Psoriasis Working Group. A study examining inter-rater and intra - rater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008; 157: 238-244.
He Z, Lu C, Basra MKA, Ou A, Yan Y, Li L. Psychometric properties of the Chinese version of dermatology life quality index (DLQI) in 851 Chinese patients with psoriasis. J Eur Acad Dermatol 2013; 27: 109-115.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Koo J, Kozma CM, Reinke K. The Development of a disease-specific questionnaire to assess quality of life for psoriasis patients: An analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002; 3: 171-179.
Linder D, Sampogna, F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. J Eur Acad Dermatol Venereol 2012; 26: 1163-1166.
Menter A., Gottlieb A, Feldman SR, et al. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659.
Jekler J, Swanbeck G. One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study. Acta Derm Venereol 1992; 72: 449-450.
Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21: 1151-1160.
Dézfoulian B, de la Brassinne M, Rosillon D. A new generation of hydrocolloid dressings in combination with topical corticosteroids in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998; 9: 50-53.
Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of calcipotriol/betamethasone dipropionate two-compound product (Dovobet/ Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-326.
Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-738.
Kudish AI, Lyubansky V, Evseev EG, Ianetz A. Statistical analysis and inter-comparison of the solar UVB, UVA and global radiation for Beer Sheva and Neve Zohar (Dead Sea), Israel. Theoretical and Applied Climatology 2005; 80: 1-15.
Menter A., Gottlieb A, Feldman SR, et al. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-135.
Picot E, Meunier L, Picot-Debeze MC, Peyron JL, Meynadier J. Treatment of psoriasis with a 311-nm UVB lamp. Br J Dermatol 1992; 127: 509-512.
Serrao R, Davis MD. Goeckerman treatment for remission of psoriasis refractory to biologic therapy. J Am Acad Dermatol 2009; 60: 348-349.
Parrish, JA, Fitzpatrick, TB, Tanenbaum, L, Pathak, MA. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 1974; 291: 1207-1212.
Henseler T, Wolff K, Honigsman H, et al. The European PUVA-Study: a cooperative study among 18 european centres. Lancet 1981; 8225: 853-857.
Henseler T, Christophers E, Hönigsmann H, et al. Skin tumours in the european PUVA study. J Am Acad Dermatol 1987; 16: 108-116.
Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Pho-tochemotherapy Follow-up Study. Cancer 1994; 73: 2759-2764.
Menter A., Gottlieb A, Feldman SR, et al. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008; 33: 551-554.
Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Harrley AH. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
Wain EM, Darlin MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 2010; 162: 427-434.
Menter A., Gottlieb A, Feldman SR, et al. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-174.
Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (suppl. 69): 3-17.
Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffits CEM. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727.
Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, Efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013.
Garcovich S, Ruggeri A, D'Agostino M, et al. Clinical applicability of Quantiferon- TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012; 26: 1572-1576.
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as Monotherapy in Patients with Psoriasis. N Engl J Med 2003; 349: 2014-2022.
Paller AM, Siegfried EC, Langley RG, et al. Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. N Engl J Med 2008; 358: 241-251.
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol 2011; 12: 51-52.
Koutruba N, Emer J, Lebwohl. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management 2010; 6: 123-141.
Griffiths CEM, Strober, BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.